2215 Yukon St
16 articles with AbCellera
AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555), a human antibody developed through AbCellera’s collaboration with Eli Lilly and Company (Lilly), will be evaluated in a new pragmatic study in high-risk patients with COVID-19. Lilly’s trial
12/16/2020A roundup of life sciences companies raking in the cash.
12/11/2020Another four companies join the Nasdaq, bringing the life science IPO count to over 70 this year.
December is bringing frost in the North and plenty of cold, hard cash for these life sciences companies.
With support from Peter Thiel, Eli Lilly partner AbCellera looks to join the NASDAQ with the biggest Canadian biotech debut on record.
AbCellera, a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease, announced the appointment of Peter Thiel to its Board of Directors.
AbCellera, a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease, and Invetx, a pioneer in protein-based therapeutics for animal health, announced the companies have expanded their agreement to generate therapeutic antibody candidates for serious and chronic conditions in animal health.
AbCellera-Discovered Antibody Receives U.S. FDA Emergency Use Authorization as a Monotherapy for the Treatment of COVID-19
AbCellera’s partner, Eli Lilly and Company, will supply the U.S. government with 300,000 doses of bamlanivimab for allocation to high-risk patients
Bamlanivimab, an intravenous treatment, should be administered as soon as possible after a positive COVID-19 test and within 10 days of symptom onset.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 10, 2020.
AbCellera and Kodiak Sciences have announced a new partnership to create and develop therapeutic antibodies for ophthalmologic indications. The two companies originally entered a partnership in August 2016.
AbCellera and Kodiak Sciences Enter Second Antibody Discovery Collaboration for Ophthalmology Targets
AbCellera and Kodiak Sciences Inc., announced a new partnership to generate therapeutic antibody candidates in ophthalmology.
AbCellera Acquires OrthoMab Bispecific Platform to Propel the Development of Antibody Therapies for Pharma and Biotech Partners
Technology expansion provides AbCellera with the ability to combine any two antibodies generated through its discovery platform to create full IgG bispecifics Computational protein engineering expert Dr. Tim Jacobs joins AbCellera from Dualogics VANCOUVER, British Columbia--( BUSINESS WIRE )-- AbCellera today announced the acquisition of the OrthoMab bispecific platform from Dualogics, LLC. (Dualogics). OrthoMab is a clinically validated pla
AbCellera Provides COVID-19 Program Update with the Start of Phase 3 Clinical Trials and the Expansion of its COVID-19 Antibody Database
AbCellera Provides COVID-19 Program Update with the Start of Phase 3 Clinical Trials and the Expansion of its COVID-19 Antibody Database As LY-CoV555 advances into Phase 3 COVID-19 prevention studies, AbCellera’s COVID-19 database reaches over 2,000 new antibodies against the virus, discovered from recovered patient samples
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 3, 2020.
AbCellera Announces Agreement with Alloy Therapeutics to Integrate Access to ATX-Gx™ Humanized Mice Platform for Antibody Discovery Programs
AbCellera Announces Agreement with Alloy Therapeutics to Integrate Access to ATX-Gx ™ Humanized Mice Platform for Antibody Discovery Programs By using humanized rodents as a source of diversity, AbCellera’s platform provides partners with the fastest path to large panels of high-quality fully human antibodies